Lupin posts robust numbers despite higher expenses

A Pharma frontliner, Lupin has posted robust Q4FY16 results where revenues and PAT have shown a double digit growth from both last quarter and corresponding quarter of last year. Lupin stock has remained positive throughout the day.

Company’s consolidated revenue for Q4FY16 was Rs 4091.32 crore as against Rs 3357.66 crore in the previous quarter, recording an increase of 21.9 per cent. EBITDA has seen an increase of 55.9 per cent from Rs 877.15 crore to Rs 1367.41 crore. Net profits too have come in at Rs 807.08 crore as compared to Rs 529.75 crore, an increase of 52.4 per cent, despite of an increase in tax and interest expenses.

Year on year revenues for the company have grown at 34 per cent and stand at Rs 3054.04 crore. EBITDA has risen by 73.2 per cent and stands at Rs 789.39 crore. YoY net profits for the same quarter last year stood at Rs 547.01 crore.

Yearly results show that Lupin’s revenues for the year ended March 2016  have posted a rise of 8.7 per cent to Rs 13701.56 as against Rs 12599.71 crore. EBITDA has risen 3.7 per cent to Rs 3753.45 crore from Rs 3619.59. However, net profits have declined 5.5 per cent to Rs 2270.69 crore amid increased tax and interest expenses.

Lupin is an India based transnational pharma company that deals in production, development and marketing of branded and generic formulations, and active pharmaceutical ingredients. The Company manufactures products in the therapy areas, such as anti-TB, cardiovascular, anti-asthma, diabetology, central nervous system, gynaecology, gastro-intestinal (GI), anti-infective and others.